Researchers have comprehensively analyzed the incidence of adverse events in trials of PD-1 and PD-L1 inhibitors, while another team has provided insight into the potential pathophysiologic process underlying these effects.
A US chart review has found no increase in the incidence of severe immune-related adverse events among advanced cancer patients who receive an influenza vaccination during the 2 months before or after initiating immune checkpoint inhibitor therapy.
An updated analysis of the CheckMate 067 trial shows continued survival benefits at 4 years with nivolumab plus ipilimumab or nivolumab monotherapy versus ipilimumab alone in patients with previously untreated advanced melanoma.
In patients with high-risk resectable melanoma, neoadjuvant treatment with the combination of nivolumab and ipilimumab is associated with high response rates but also considerable toxicity, while single-agent nivolumab has better tolerability but is less efficacious, trial results show.
Using 18F-fluorodeoxyglucose–positron emission tomography to measure treatment response at 1 year in patients with metastatic melanoma may better predict long-term outcomes than standard computed tomography, research shows.